Microsatellite instability (MSI) in tumors is diagnostic for inactive DNA mismatch repair. It is widespread among some tumor types, such as colorectal or endometrial carcinoma, but is rarely found in leukemia. Therapyrelated acute myeloid leukemia/myelodysplastic syndrome (tAML/MDS) is an exception, and MSI is frequent in tAML/MDS following cancer chemotherapy or organ transplantation. The development of MSI + tumors is associated with an accumulation of insertion/deletion mutations in repetitive sequences. These events can cause inactivating frameshifts or loss of expression of key growth control proteins. We examined established MSI + cell lines and tAML/MDS cases for frameshift-like mutations of repetitive sequences in several genes that have known, or suspected, relevance to leukemia. CASPASE-5, an acknowledged frameshift target in MSI + gastrointestinal tract tumors, was frequently mutated in MSI + cell lines (67%) and in tAML/MDS (29%). Frameshiftlike mutations were also observed in the NF1 and FANCD2 genes that are associated with genetic conditions conferring a predisposition to leukemia. Both genes were frequent targets for mutation in MSI + cell lines and colorectal carcinomas. FANCD2 mutations were also common in MSI + tAML/MDS, although NF1 mutations were not observed. A novel FANCD2 polymorphism was also identified. (Mol Cancer Res 2005;3(5):251 -60) 
Introduction
Cancer arises by a process of somatic mutation and selection, and its development is influenced by the rate of spontaneous somatic mutation. DNA mismatch repair (MMR) normally provides protection against mutation by correcting DNA replication errors. As expected, MMR deficiency is associated with an increased mutation rate and with cancer (for review, see ref. 1) . A significant fraction of certain tumorsnotably, but not exclusively, those of endometrial, colorectal, and other gastrointestinal sites-are MMR defective. In the MMR pathway, proteins encoded by the MSH2, MLH1, PMS2, MSH6, and MSH3 genes form a series of heterodimeric complexes that recognize promutagenic replication errors and initiate their correction. A defect in any of these proteins compromises repair efficiency (reviewed in ref. 2) .
MMR is particularly efficient at reversing unpaired nucleotides that arise during replication of DNA regions comprising extensive mononucleotide or dinucleotide repeats of the type found in microsatellites. If they remain uncorrected, these structural aberrations cause insertion/ deletion mutations, which alter the length of the repeat. MMR-deficient tumors contain many thousands of altered microsatellite sequences (3, 4) and have been described as having a microsatellite mutator phenotype or microsatellite instability (MSI). In practice, MSI is usually defined as alterations in a significant fraction of a standard panel of five microsatellites in tumor DNA. This is considered diagnostic for defective MMR. MSI + tumors do not, in general, exhibit widespread chromosomal rearrangements or aneuploidy (5) . This most likely reflects at least partially distinct pathways of tumor development that accompany MSI and chromosomal instability. MSI is particularly associated with the accumulation of inactivating frameshifts in repetitive elements, resembling microsatellites but located within coding sequences of critical tumor suppressor genes. Transforming growth factor-h (TGF-h) provides a good example (6) . Escape from the growth restraints imposed by TGF-h is common in the development of colorectal cancer. The TGFb-RII gene, which encodes a component of the TGF-h receptor contains an A 10 sequence. In MSI + colorectal tumors, TGFb-RII is almost invariably inactivated by a frameshift in this repeat. These mutations are rare in MMRproficient, MSI À colorectal tumors. The key gene products that impose normal growth control are tissue dependent, and TGFb-RII mutations are also infrequent in MSI + tumors from tissues that are not normally TGF-h responsive. Other examples of genes that are susceptible to inactivating frameshifts in MSI + tumors include BAX (7), RAD50, and BLM (8) . Each of these contains a repeat of eight or more mononucleotides in coding DNA sequences.
Extensive mononucleotide or dinucleotide repeats are rare in exonic DNA sequences. Uninterrupted monotonic repeats occur more frequently in the pyrimidine-rich tract that precedes mRNA splice acceptor sites. Small insertions or deletions in these intronic sequences can cause exon skipping and mRNA instability. In one example, the single-base alterations in an intronic T 11 tract of the MRE11 cell cycle checkpoint/DNA repair gene that are common in established MSI + tumor cell lines and, importantly, in MSI + colorectal tumors (9) , cause defects in the DNA damage response. Mutated cells fail to arrest DNA replication after exposure to ionizing radiation and are sensitive to radiomimetic agents.
The proportion of sporadic tumors that are MSI + varies with the tumor type and location. For example, 15% to 20% of sporadic colorectal or endometrial carcinomas are MSI + , whereas the phenotype is notably rare in leukemia and affects <5% of cases. Therapy-related acute leukemia is an important exception (reviewed in ref. 10) . Probably more than half of acute myeloid leukemia/myelodysplastic syndrome (AML/ MDS) cases that occur secondary to successful chemotherapy are MSI + (11) (12) (13) (14) . We recently reported a high incidence of MSI among AML/MDS cases from solid organ transplant patients who received prolonged treatment with immunosuppressive drugs (15) . We have suggested that MMR defects in chemotherapy or immunosuppression-related AML/MDS (tAML/MDS) reflect the intrinsic drug resistance of MSI + myeloid cells (16) .
If loss of MMR is an early step in tAML/MDS, frameshift mutations in key genes regulating normal hematopoiesis may be important in the development of these secondary malignancies. To understand how MSI + tAML/MDS might develop, it is necessary to define the relevant frameshift targets. Here, we show that CASPASE-5, a gene acknowledged to be a frameshift target in other tumor types, is also mutated in MSI + tAML/MDS. In addition, we identify an intronic T 26 sequence in the NF1 gene as a target for insertion/deletion mutations in MSI + tumors. Mutations in this sequence were frequent in MSI + colorectal carcinoma but not in tAML/MDS. A mononucleotide intronic repeat in the FANCD2 gene, an important determinant of genetic stability, is identified as target for insertion/deletions in colorectal carcinoma and tAML/MDS. A novel polymorphism in this sequence is also described. Table 1 lists the genes that were analyzed and Fig. 1 indicates the location and nature of each repeat sequence. Most of the repetitive elements comprise z7 mononucleotides. We also examined a (TG) 5 repeat in FANCG and a (T) 6 sequence in NF1. The putative targets fall into three broad classes: genes known to be mutated by insertion or deletion in MSI + tumors (e.g., CASPASE-5), genes implicated in the development of AML or associated with particular susceptibility to AML/MDS (e.g., FANCD2 and NF1), and tumor suppressor genes that have not been identified previously as frameshift targets (e.g., RB). Sequences were identified from the ENSEMBL database (http://www.ensembl.org/).
Results

Putative Frameshift Targets
CASPASE-5 and NF1 Mutations in MSI
+ Tumor Cell Lines Twelve established MSI + tumor cell lines and 2 MMRdeficient cell lines selected by in vitro treatment (RajiF12 and A2780-MNUcl1) were compared with 6 MMR-proficient lines ( Table 2 ). The regions of interest were amplified with fluorescent primers and the length of the fluorescent products was used to define a genotype. The approach was validated using the A 10 repeat of CASPASE-5, which is a known target for mutation in MMR-deficient cells. Examples of genotyping and direct sequencing are shown in Fig. 2 . The CASPASE-5 A 10 sequence was intact in all five MMR-proficient cell lines we examined. Eight of 12 (67%) MMR-defective cell lines contained a one-base deletion in at least one CASPASE-5 T 10 allele ( Table 2 ). In two cases, only the T 9 allele was observed, consistent with biallelic mutations or loss of heterozygosity. The high frequency of CASPASE-5 alterations in these cell lines is consistent with published reports of frequent CASPASE-5 mutations in MSI + gastrointestinal, endometrial, and other tumors. The perfect correspondence between the sequencing data and genotyping indicates that the fluorescent PCR-based method provides a sensitive and accurate analysis of frameshift target sequences.
An uninterrupted T 26 repeat precedes the splice acceptor site in intron 24/25 of the NF1 gene on chromosome 17 (Fig. 1) . We amplified a 232-nucleotide region that included the T 26 repeat. The PCR products from the four MMR-proficient cell lines we examined were all closely similar with two predominant peaks of similar intensity that corresponded to 232 and 231 nucleotides (Fig. 3A) . The shorter product is consistent with errors during PCR of this long repeat. This region was altered in five of five MMR-defective cell lines consistent with considerable instability of the T 26 repeat (Table 2 ). In each case, the mutated alleles were shorter and the extent of the change ranged from f3 to 9 nucleotides (Table 2 ; examples in Fig. 3A ).
To investigate whether the NF1 microsatellite mutations caused exon skipping, we examined mRNA from LoVo or SW48 cells, both of which contained mutated NF1 alleles, and SW480 and HeLa cells, in which the NF1 genotype was normal. A skipped NF1 exon 25 would result in a deletion of 117 nucleotides. Reverse transcription-PCR (RT-PCR) amplification of the region between mid-exons 23 and 26 produced the expected 383-nucleotide product from MMR-proficient SW480 and HeLa cells. A product of apparently identical size was amplified from MMR-defective LoVo and SW48 and there was no evidence of a truncated 266-nucleotide species (Fig. 3B) . The presence of an intact exon 25 in LoVo and SW48 NF1 mRNA was confirmed by direct sequencing (data not shown). We conclude that the intronic T 26 microsatellite in intron 24/25 of NF1 is a frequent target of mutation in MMRdefective cells but that these mutations do not cause deletion of exon 25. 
NOTE: ND, not determined. The two short NF1 exonic pyrimidine repeats, C 7 in exon 18 and T 6 in exon 36 ( Fig. 1) , were not mutated in our panel of MMR-defective cell lines (data not shown).
No mutations in the A 9 or A 7 repeats of the CHK1 gene, the T 9 repeat of FAS, and the T 9 repeat of RB were detected in any of the MSI + cell lines (data not shown). For this reason, these sequences were not considered further.
+ Malignancies In a previous study, 16 MSI + chemotherapy-related leukemias were identified among a total of 25 cases (14) . We examined the A 10 repeat of CASPASE-5 in 22 of the cases for which sufficient DNA remained. Three MSI + cases were heterozygous for a single-base deletion (A 9 /A 10 ). The remaining 11 and 8 MSI À cases all had the wild-type A 10 genotype (Table 3) . Interestingly, one of the CASPASE-5 mutations was in case 8 that we previously designated MSI stable (14) based on analysis of the BAT26 microsatellite. Recently, doubts have been raised as to the informativeness of BAT26 as a unique diagnostic marker for MSI in tAML (17) . In view of this, and the finding that both the CASPASE-5 A 10 tract and the FANCD2 T 10 tract (see below) are altered in case 8, it seems appropriate to reclassify it as MSI + . We also examined CASPASE-5 in six cases of MSI + AML/ MDS from organ transplant patients (15) . A sample of the explanted heart or lung provided a source of nontumor DNA. All nontumor tissues had the expected A 10 genotype (Table 4) . Two AML/MDS cases were heterozygous for A 10 /A 9. For case 2, the T 10 /T 9 genotype was confirmed in a second, independent biopsy. Because CASPASE-5 mutations were found in 5 of 17 (29%) of the cancer therapy-related and immunosuppression-related tAML/MDS cases, we conclude that frameshifts in the CASPASE-5 A 10 repeat are common in this group of diseases.
No mutations in the NF1 T 26 sequence were observed among nine chemotherapy-related AMLs examined. Four MSI + cases and 5 microsatellite-stable cases were indistinguishable from 10 normal blood donors. All 19 samples produced a similar 231/232-nucleotide pattern characteristic of the T 26 sequence in the microsatellite-stable cell lines (examples in Fig. 3A ). This consistent pattern indicates that the NF1 T 26 microsatellite is likely to be monodisperse in the normal population. There was no indication of instability at this locus in five MSI + transplant-related AMLs (Table 4) . Because the apparent stability of the NF1 T 26 microsatellite in the tAML/MDS cases was surprising in view of its frequent mutation in the MSI + cell lines, we also analyzed a series of colorectal carcinoma DNAs. The normal 231/232-nucleotide pattern was observed in 17 of 17 MSI À samples. In four of five MSI + colorectal carcinoma, there was evidence of instability and we observed deletions ranging Fig. 3A ). These data confirm that the NF1 T 26 sequence is a frequent mutational target in MSI + tumors as well as established cell lines. Surprisingly, these NF1 mutations seem uncommon in MSI + tAML/MDS cases.
The exonic C 7 or T 6 repeats of NF1 were not mutated in any of the MSI + or MSI À tumors (data not shown).
FANCD2
A FANCD2 Polymorphism. Fanconi anemia is associated with a high incidence of AML. We therefore sought potential frameshift targets in the Fanconi anemia genes. The ENSEMBL database revealed three possibilities: a FANCE C 7 repeat, (TG) 5 in FANCG, and T 10 immediately adjacent to the splice acceptor site for intron 5/6 of FANCD2 (Fig. 1) .
No mutations were observed in the FANCE or FANCG repeats in any of the cell lines irrespective of MMR status (data not shown). Direct sequencing of the FANCD2 T repeat confirmed the presence of the T 10 tract in MMR-proficient cell lines and normal individuals. In some cases, however, sequencing data suggested the presence of a shorter allele. Subsequent genotyping confirmed the presence of a T 8 allele in these cases. Figure 4A shows examples of the T 10 /T 8 and T 10 genotypes from microsatellite-stable cells together with the corresponding sequencing data. When present, the T 8 allele was consistently observed in repeat determinations, indicating that it is unlikely to be a PCR or sequencing artifact. (Table 2) . Among the 14 MMR-defective cell lines, novel alleles were observed in Jurkat (T 9 ), SW48 (T 11 ), HCT116 (T 11 ), and REH (T 11 ). Examples of altered alleles in MSI + cells are shown in Fig. 4B . There were also two examples of apparent homozygosity for T 8 in this series. The remaining eight cell lines were either T 10 or T 10 /T 8 . It was noteworthy that all the lines retained at least one T 10 or T 8 allele. The T 11 and T 9 alleles together comprise f15% of the total among the MMR-deficient cells. The T 8 allele frequency was f0.3 in these cell lines, close to the frequency in repair-proficient samples. In view of the instability of this tract, it is possible that some of these T 8 alleles arose by mutation, however. The frequent occurrence of novel T 9 or T 11 alleles indicates that this repeat is a significant target for mutation in MSI + cells.
FANCD2 Mutations in MSI
+ Malignancies. The FANCD2 repeat was also mutated in MSI + tumors. There were two examples of T 9 among 5 MSI + colorectal cancers (40%). In one of these, T 9 was the only allele observed. Among 22 chemotherapy-related AML samples, all MSI À cases were either T 10 (7 cases) or T 10 /T 8 (1 case; Table 3 ). Of the 14 MSI + cases, 8 were T 10 and 3 were T 10 /T 8 . There was a single example each of apparent homozygosity for T 9 and for T 8 . In one sample (case 8; see above), all three alleles were repeatedly observed. Patterns consistent with mutation were observed in the transplant-related AML/MDS samples (Table 4) . In case A3, the explanted tissue had a T 10 genotype. In contrast, the AML/MDS was T 10 /T 8 , suggesting that the T 8 allele arose as the result of a mutation. In case A2, the constitutive genotype was T 10 /T 8 , whereas the AML/MDS was T 8 . This change is also consistent with a two-base deletion, although it could also have occurred by loss of the T 10 allele.
In summary, a (T 8 ) variant of the T 10 mononucleotide repeat that precedes the intron 4/5 splice acceptor site of FANCD2 seems to be a novel polymorphism that is relatively rare in the normal population. In a MMR-defective background, the FANCD2 repeat is a target for insertion or deletion mutation. The frequency of these mutations is high and they were observed in 15% to 40% of MSI + cell lines and tumors.
Effect of Repeat Length on the Function of FANCD2. Representatives of each of the FANCD2 genotypes were analyzed by RT-PCR. In each case, the major product was of the length expected for a full-length FANCD2 mRNA (Fig. 4C) . A minor, shorter product was also present (Fig. 4C, arrow) . This was most apparent in LoVo and AN3CA, although it was detected in all of the samples, including MSI À ones, by more sensitive staining (data not shown). These truncated cDNA products were sequenced and alignment by BLAST 2 search indicated that they were identical to FANCD2 with a deleted exon 8 (data not shown). Skipping exon 8 generates a premature stop codon in exon 9. Because this aberrant splice variant is present in all cell lines, irrespective of MMR status, we conclude that it probably is not a consequence of mutation and is unlikely to be physiologically relevant. There was no evidence of a cDNA product corresponding to a skipped exon 6, the expected outcome of altered splicing due to alterations in the intronic T 10 /T 8 sequence.
Homozygous inactivation of FANCD2 causes a dramatic increase in sensitivity to DNA cross-linking agents, such as mitomycin C. To assess whether homozygosity for the less frequent T 8 allele, or the presence of a mutant allele affected sensitivity to cross-linking agents, we examined the growth of Raji (T 10 /T 8 ), Molt4 (T 8 ), and REH (T 10/11 ) after treatment with mitomycin C. Although there were slight differences, there was no indication of dramatic mitomycin C sensitivity that would be consistent with a severely compromised FANCD2 function (Fig. 5A) .
The FANCD2 protein exists in two isoforms (FANCD2-S and FANCD2-L) that can be resolved by Western blotting. Under normal conditions, FANCD2-S predominates. Following DNA damage, FANCD-2 is monoubiquitinated and converted to the more slowly migrating FANCD2-L form (18) . We investigated whether conversion to the FANCD2-L form was impaired in cells of the T 8 genotype. Figure 5B shows that exposure to ionizing radiation induced conversion of FANCD2-S to FANCD2-L in Raji (T 10 /T 8 ), GM00621(T 8 ), and Molt4 (T 8 ) cells. Taken together with the absence of acute sensitivity to mitomycin C, these findings suggest that the T 8 isoform is not associated with a severe impairment of FANCD2 protein function.
Discussion
The identification of mutational targets for insertion/deletion mutations in MSI + tAML is a prerequisite for understanding how MSI + tAML develops. Our data indicate that an acknowledged frameshift target in CASPASE-5 and a previously unidentified target in that included several of colorectal origin. About 20% of our MSI + tAML cases had similar CASPASE-5 mutations in broad agreement with other reports (22, 23), although Olipitz et al. (24) found no CASPASE-5 mutations in five therapy-related leukemias. The precise function of the CASPASE-5 protein is not known. Although they are involved in apoptosis, proteases of the caspase group to which CASPASE-5 belongs seem to be involved in regulating inflammatory responses (25) . The frequent occurrence of frameshifts in the A 10 repeat of CASPASE-5 in MSI + tumors suggests that CASPASE-5 may protect against tumorigenesis. Because 20% of MSI + tAMLs also contained CASPASE-5 mutations, this protection also seems to be significant in hematologic malignancy.
Type 1 neurofibromatosis (NF1) is a common autosomal dominant disorder characterized by neurofibromas and multiple café au lait spots. The NF1 gene is considered to be a tumor suppressor in myeloid cells and NF1 individuals have an estimated 200-to 500-fold elevated risk of myeloid malignancy and myelodysplasia (reviewed in ref. 26) . Concerning tAML/ MDS, it is particularly interesting that alkylating agent treatment accelerates the development of myeloid malignancy in Nf1 heterozygous mice (27) . Defective MMR is associated with NF1. Homozygosity for the MSH2 or MLH1 mutations that predispose heterozygous individuals to hereditary nonpolyposis colorectal carcinoma in adulthood results in a childhood condition with the clinical features of NF1 and hematologic malignancies (28) (29) (30) . This suggests that NF1 might be particularly susceptible to mutation in MMR-deficient cells. Consistent with this view, NF1 mutations were found to be more frequent in MSI + than in microsatellite-stable tumors (31) . In addition, a MMR defect significantly accelerates the development of myeloid leukemia in Nf1 heterozygous mice (32) . We examined three potential frameshift targets: the short exonic C 7 and T 6 repeats and the T 26 intronic microsatellite. No mutations were found in the short repeats, although a single-base deletions have been reported in the MSI + colorectal carcinoma HCT116 (-C) and LoVo (-T) cell lines (31) . (We did not observe the T deletion in our LoVo cells, suggesting that the reported mutation had occurred during culture in vitro and was not present in the original tumor.) The T 26 repeat was a frequent mutational target in MSI + cell lines and colorectal carcinomas. RT-PCR provided no evidence of mRNA splicing defects in cell lines with a mutated T 26 , although this analysis does not preclude the possibility of subtle effects. Surprisingly, in view of the association between defective MMR and neurofibromatosis, all MSI + AML/MDS cases we examined retained wild-type NF-1. Fanconi anemia is an autosomal recessive disorder comprising eight complementation groups. In addition to lifethreatening pancytopenia, Fanconi anemia individuals have a very high risk of developing AML. Cells from Fanconi anemia patients are extremely sensitive to DNA cross-linking agents, such as mitomycin C or diepoxybutane (for recent reviews, see refs. 33, 34) . There are interesting parallels between the AML in Fanconi anemia patients and tAML/MDS. Cytogenetic abnormalities (5q-, monosomy 7, and 7q-) commonly found in AML of Fanconi anemia patients (35) are strikingly similar to those found in tAML/MDS. These changes are relatively infrequent in de novo AML (33, 34) . In addition, AML in Fanconi anemia patients is generally preceded by a myelodysplastic phase (36) , again more closely resembling tAML/MDS rather than de novo disease. One possible implication of these similarities is that acquired defects in the Fanconi anemia pathway of DNA damage signaling and repair might contribute to the development of tAML/MDS. Because the majority of tAML/MDS cases are MSI + , we examined putative frameshift targets in Fanconi anemia genes. Although no mutations were identified in a C 7 repeat in FANCE or a (TG) 5 repeat in FANCG in any of the MSI + cell lines, frequent addition/deletion mutations were found in the intronic T repeat of FANCD2. Although FANCD2 is clearly a target for mutation in MSI + tumors, mRNA splicing, drug sensitivity, and DNA damagedependent FANCD2 protein ubiquitination were not detectably impaired in mutated cells. The RT-PCR method was, however, sufficiently sensitive to detect a rare FANCD2 splice variant that results from skipping exon 8. We note that none of the cell lines were homozygous for the mutant T 9 allele, although this genotype was observed in tumors. It would be of interest to examine mRNA expression, drug sensitivity, and FANCD2 ubiquitination in cells with the T 9 genotype.
The FANCD2 T 8 variant seems to be a previously unidentified polymorphism. Among normal individuals, MMR-proficient tumor cell lines, and colon cancers (46 samples in total), the frequencies of the T 10 and T 8 alleles were f0.8 and 0.2, respectively. We found only a single example of apparent homozygosity for T 8 among non-MSI + cells. Because this was in an EBV-transformed lymphoblastoid cell line that has been maintained in culture for many years, the true frequency of the T 8 / T 8 genotype in the normal population remains to be determined.
In summary, we have identified targets for insertion/deletion mutations in MSI + AML/MDS. One of these is an acknowledged target in the CASPASE-5 gene. The other is an intronic repeat within FANCD2 in which we also identified a rare polymorphism. Mutations in the FANCD2 repeat were identified in MSI + AML/MDS cases as well as in colorectal tumors and cell lines. A more limited analysis indicated that an intronic T 26 microsatellite in NF1 is a common target in MSI + colorectal carcinomas but not in tAML/MDS. Whether this reflects selection against NF-1 mutations in developing myeloid malignancy is an interesting possibility confirmation of which awaits analysis of more MSI + AML/MDS cases. None of the intronic mutations caused severe impairment of mRNA splicing and no gross alterations in sensitivity to a DNA crosslinking agent could be ascribed to heterozygosity for mutated FANCD2 or homozygosity for the rare allele. The possibility of subtle defects resulting from two mutated FANCD2 alleles or singly in combination with hypomorphic mutations or polymorphisms in other DNA repair functions is not excluded, however, and might repay further investigation.
Materials and Methods
Patient Material
Genomic DNA was obtained from chemotherapy-related (14) and transplant-related AMLs (15) as described previously. 
Cell Lines
All cell lines used were obtained from Cancer Research UK London Research Institute Central Cell Repository. The MMRdefective variants A2780-MNUcl1 (37) and RajiF12 (38) have been described previously.
Sensitivity to Mitomycin C
Exponentially growing cells were seeded at a concentration of 5 Â 10 5 /mL in 24-well plates and grown in the continuous presence of mitomycin C. Cell numbers were determined by daily hemocytometer counts. Throughout the experiment, exponential growth was maintained by appropriate dilution into growth medium.
Preparation of Total RNA
Cultured cells were harvested during exponential growth. RNA was prepared using a Qiagen (Crawley, United Kingdom) RNeasy Mini kit according to the manufacturer's instructions. Samples were homogenized using Qiashredders (Qiagen). A DNase digestion step was included using the Qiagen RNaseFree DNase Set according to the manufacturer's instructions.
Target Gene Analysis
Genotyping. The CASPASE-5, CHK1, FAS, RB, NF1, FANCD2, FANCE, and FANCG repeat sequences were amplified by PCR using fluorescent primers ( Table 1 ). The sense primer of each primer set was FAM labeled at its 5V terminus. Fragments were amplified as multiplex PCRs: CASPASE-5 and FANCD2; CHK1, FAS, and RB; FANCE and FANCG; or individually (NF1). Genomic DNA (10 pg-20 ng) was amplified with 10 pmol of each primer. After initial denaturation at 95jC for 15 minutes, 30 to 40 amplification cycles were followed by a final extension at 72jC for 10 minutes. Each amplification cycle was 30 seconds at 94jC, 90 seconds at 55jC to 63jC, and 60 seconds at 72jC. For DNA from clinical samples, the annealing time was increased from 90 seconds to 3 minutes. Products were analyzed either on an ABI Prism 377 sequencer or an ABI Prism 3100 capillary system. Data were analyzed using the Genotyper 1.1 software.
DNA Sequencing. PCR reactions were done as described above but using nonfluorescent primers. PCR products were separated by electrophoresis through 2% agarose gels. The PCR products were excised, purified with the Qiagen Gel Purification kit, and sequenced using the BigDye Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems, Warrington, United Kingdom) according to the manufacturer's instructions. Data were analyzed using the Genotyper 1.1 software.
Reverse Transcription-PCR
Total cellular RNA (1 Ag) was reverse transcribed in ImProm-II Reaction Buffer (Promega, Southampton, United Kingdom) containing 20 units RNasin RNase inhibitor (Ambion, Huntington, United Kingdom), 10 mmol/L deoxynucleotide triphosphates, 3 mmol/L MgCl 2 , 0.5 Ag pd(N) 6 random hexamer primers (Amersham Pharmacia Biotech, Amersham, United Kingdom), and 1 AL ImProm-II Reverse Transcriptase according to the manufacturer's instructions. FANCD2 cDNA was coamplified with h-actin as a positive control. The reverse-transcribed product was amplified in 1Â Multiplex PCR Master Mix containing 10 pmol appropriate primer pairs. After initial denaturation at 95jC for 15 minutes, 35 cycles of amplification were followed by a final extension at 72jC for 10 minutes. Each cycle was 30 seconds at 94jC, 90 seconds at 57jC, and 60 seconds at 72jC. The NF1 and FANCD2 products were purified and sequenced as described above.
